HUTCHMED (China) Limited - American Depositary Shares (HCM) analyst actions
Rating and price-target actions on HCM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the HCM overview →
9 measured HCM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors | Press release | +0.36% | +1.44% | |
| HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China | Press release | +0.00% | -0.71% | |
| HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors | Press release | -0.59% | +0.55% | |
| HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma | Press release | -0.66% | -2.41% | |
| HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors | Press release | +0.00% | +0.15% | |
| HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China | Press release | -0.08% | -0.23% | |
| HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui | Press release | -1.70% | -1.79% | |
| HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China | Press release | -1.70% | -1.79% | |
| HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China | Press release | +0.36% | -0.73% |
Keep exploring
More HCM: earnings → · SEC filings → · HCM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MiMedx Group, Inc (MDXG) | 265 | +0.14% | 57% |
| Relmada Therapeutics, Inc. (RLMD) | 265 | -0.01% | 44% |
| iBio, Inc. (IBIO) | 263 | -0.38% | 43% |
| NOVUS THERAPEUTICS (NVUS) | 263 | -0.14% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.